Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Dec;56(6):908-919.e3.
doi: 10.1016/j.jpainsymman.2018.08.017. Epub 2018 Aug 30.

Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors

Kord M Kober  1 , Melissa Mazor  2 , Gary Abrams  3 , Adam Olshen  3 , Yvette P Conley  4 , Marilyn Hammer  5 , Mark Schumacher  3 , Margaret Chesney  3 , Betty Smoot  3 , Judy Mastick  2 , Steven M Paul  2 , Jon D Levine  3 , Christine Miaskowski  2
Affiliations
Comparative Study

Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors

Kord M Kober et al. J Pain Symptom Manage. 2018 Dec.

Abstract

Context: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors.

Objectives: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN.

Methods: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN.

Results: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning.

Conclusion: The findings from this large descriptive study are the first to document the impact of PIPN on survivors' symptom burden, functional status, and QOL.

Keywords: Paclitaxel; balance; cancer; chemotherapy; pain; peripheral neuropathy; quality of life; stress; survivor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have no conflict of interests to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agnew J, Bolla-Wilson K, Kawas CH, Bleecker ML. Purdue pegboard age and sex norms for people 40 years and older. Dev Neuropsychol. 4:29–35, 1988
    1. Anderson SG, Narayanan RP, Malipatil NS, Roberts H, Dunn G, Heald AH. Socioeconomic deprivation independently predicts painful diabetic neuropathy in type 2 diabetes. Exp Clin Endocrinol Diabetes. 123:423–427, 2015 - PubMed
    1. Arab C, Dias DP, Barbosa RT, Carvalho TD, Valenti VE, Crocetta TB, Ferreira M, Abreu LC, Ferreira C. Heart rate variability measure in breast cancer patients and survivors: A systematic review. Psychoneuroendocrinology. 68:57–68, 2016 - PubMed
    1. Beauchet O, Fantino B, Allali G, Muir SW, Montero-Odasso M, Annweiler C. Timed Up and Go test and risk of falls in older adults: a systematic review. J Nutr Health Aging. 15:933–938, 2011 - PubMed
    1. Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol. 54:463–469, 2015 - PubMed

Publication types

Substances